Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Lancet Haematol. 2020 Sep 5;7(10):e724–e736. doi: 10.1016/S2352-3026(20)30210-6

Figure 2.

Figure 2

a. Overall survival (OS) in all patients and b. duration of CR/CRi in responding patients with ten-day decitabine and venetoclax. ND = newly diagnosed, sAML = secondary AML, R/R = relapsed or refractory, NR = not reached, CI = confidence interval, mo = months.